Reaching the limits of prognostication in non-small cell lung cancer: An optimized biomarker panel fails to outperform clinical parameters

Modern Pathology

Volumn 30, Issue 7, 2017, Pages 964-977

  Grinberg, Marianna ^a   Djureinovic, Dijana ^b   Brunnström, Hans R R ^c   Mattsson, Johanna S M ^b   Edlund, Karolina ^a   Hengstler, Jan G ^a   La Fleur, Linnea ^b   Ekman, Simon ^b   Koyi, Hirsh ^b,d   Branden, Eva ^b,d   Ståhle, Elisabeth ^e   Jirström, Karin ^c   Tracy, Derek K ^f   Pontén, Fredrik ^b   Botling, Johan ^b   Rahnenführer, Jörg ^a   Micke, Patrick ^b  

^a TU DORTMUND UNIVERSITY   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d GÄVLE HOSPITAL   (Sweden)

^e OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE 1; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NKX2.1; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; HOMEOBOX PROTEIN NKX 2.1; MKI67IP PROTEIN, HUMAN; NKX2-1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; SLC2A1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL PREDICTION; TISSUE MICROARRAY; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULE-1; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; NUCLEAR PROTEINS; PROGNOSIS; THYROID NUCLEAR FACTOR 1; TISSUE ARRAY ANALYSIS;

EID: 85014751746     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2017.14     Document Type: Article

References (62)

1. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:4-9
2. Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev 2015;2: CD011430
3. Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008;3:457-466
4. Botling J, Edlund K, Lohr M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 2013;19:194-204
5. Lindskog C, Edlund K, Mattsson JS, et al. Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use? Expert Rev Mol Diagn 2015;15:471-490
6. Micke P, Edlund K, Holmberg L, et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol 2011;6:1833-1840
7. Zhu CQ, Tsao MS. Prognostic markers in lung cancer: is it ready for prime time? Transl Lung Cancer Res 2014;3: 149-158
8. Wen J, Fu J, Zhang W, et al. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod Pathol 2011;24:932-943
9. Zhu CQ, Shih W, Ling CH, et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800
10. Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012;72:6097-6101
11. Director's Challenge Consortium for the Molecular Classification of Lung A, Shedden K, Taylor JM, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-827
12. Tang H, Xiao G, Behrens C, et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in nonsmall cell lung cancer patients. Clin Cancer Res 2013;19:1577-1586
13. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010;28:4417-4424
14. Gold KA, Kim ES, Liu DD, et al. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res 2014;20:1946-1954
15. D'Amico TA, Massey M, Herndon JE 2nd, et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117:736-743
16. Micke P, Mattsson JS, Djureinovic D, et al. The impact of the fourth edition of the WHO classification of lung tumours on histological classification of resected pulmonary NSCCs. J Thorac Oncol 2016;11: 862-872
17. Tran L, Mattsson JS, Nodin B, et al. Various antibody clones of napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic diagnostics of non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol 2015;24:648-659
18. Djureinovic D, Hallström BM, Horie M, et al. Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight 2016;1:e86837
19. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714
20. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARCPress: Lyon, France, 2004: Chapter 1, pp 25-51
21. Goto A, Niki T, Chi-Pin L, et al. Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. Cancer Sci 2005;96:480-486
22. Hou J, Aerts J, den Hamer B, et al. Gene expressionbased classification of non-small cell lung carcinomas and survival prediction. PLoS ONE 2010;5:e10312
23. Xie Y, Xiao G, Coombes KR, et al. Robust gene expression signature from formalin-fixed paraffinembedded samples predicts prognosis of non-smallcell lung cancer patients. Clin Cancer Res 2011;17: 5705-5714
24. Rousseaux S, Debernardi A, Jacquiau B, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 2013;5:186ra66
25. Okayama H, Kohno T, Ishii Y, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ ALK-negative lung adenocarcinomas. Cancer Res 2012;72:100-111
26. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357
27. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66: 7466-7472
28. Der SD, Sykes J, Pintilie M, et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol 2014;9:59-64
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300
30. Edlund K, Lindskog C, Saito A, et al. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer 2012;131:2264-2273
31. Therneau T. A Package for Survival Analysis in S. Available from http://CRAN.R-project.org/package = survival (accessed on 2015)
32. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387
33. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182: 311-322
34. Kloppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90:162-166
35. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:174-183
36. Jakobsen JN, Sorensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer 2013;79:1-7
37. Nakamura N, Miyagi E, Murata S, et al. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol 2002;15:1058-1067
38. Sheppard MN. Specific markers for pulmonary tumours. Histopathology 2000;36:273-276
39. Barlesi F, Pinot D, Legoffic A, et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 2005;93:450-452
40. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009;13:1977-1986
41. Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012;72: 3091-3104
42. Jiang T, Wang Y, Zhou F, et al. Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis. Oncotarget 2016;7:4584-4597
43. Behrens C, Solis LM, Lin H, et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res 2013;19:6556-6565
44. Kunju LP, Cookingham C, Toy KA, et al. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol 2011;24:786-793
45. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-430
46. Zeng D, Wu X, Zheng J, et al. Loss of CADM1/TSLC1 expression is associated with poor clinical outcome in patients with esophageal squamous cell carcinoma. Gastroenterol Res Pract 2016;2016:6947623
47. Zhang J, Ning J, Geng J, et al. Down-regulation of tumor suppressor in lung cancer 1 (TSLC1) expression correlates with poor prognosis in patients with colon cancer. J Mol Histol 2012;43:715-721
48. Ooi AT, Gomperts BN. Molecular pathways: targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA. Clin Cancer Res 2015;21: 2440-2444
49. Barron CC, Bilan PJ, Tsakiridis T, et al. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism 2016;65:124-139
50. Shiba M, Kohno H, Kakizawa K, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer 2000;89:1457-1465
51. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-1051
52. Demarchi LM, Reis MM, Palomino SA, et al. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol 2000;13:511-520
53. Ko E, Lee BB, Kim Y, et al. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer. Clin Cancer Res 2013;19:1204-1212
54. Masuda K, Takano A, Oshita H, et al. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011;17:7712-7722
55. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824
56. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006;24:5079-5090
57. Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 2013;19:6261-6271
58. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012;379:823-832
59. Nakagawa T, Toyazaki T, Chiba N, et al. Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interact Cardiovasc Thorac Surg 2016;23:560-566
60. Yotsukura M, Ohtsuka T, Kaseda K, et al. Value of the glasgow prognostic score as a prognostic factor in resectable non-small cell lung cancer. J Thorac Oncol 2016;11:1311-1318
61. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008;21(Suppl 2):S16-S22
62. Uchino K, Ito A, Wakayama T, et al. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung. Cancer 2003;98:1002-1007